Tekla Life Sciences Investors HQL
We take great care to ensure that the data presented and summarized in this overview for TEKLA LIFE SCIENCES INVESTORS is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HQL
View all-
Saba Capital Management, L.P. New York, NY3.43MShares$44.2 Million1.11% of portfolio
-
Penserra Capital Management LLC Orinda, CA828KShares$10.7 Million0.2% of portfolio
-
Karpus Management, Inc. Pittsford, NY490KShares$6.31 Million0.23% of portfolio
-
Sit Investment Associates Inc Minneapolis, MN417KShares$5.37 Million0.12% of portfolio
-
Absolute Investment Advisers LLC400KShares$5.15 Million0.67% of portfolio
-
Morgan Stanley New York, NY366KShares$4.71 Million0.0% of portfolio
-
Needham Investment Management LLC New York, NY353KShares$4.54 Million0.4% of portfolio
-
Lpl Financial LLC Fort Mill, SC287KShares$3.7 Million0.0% of portfolio
-
Flagship Harbor Advisors, LLC250KShares$3.23 Million0.18% of portfolio
-
1607 Capital Partners, LLC Richmond, VA247KShares$3.18 Million0.26% of portfolio
Latest Institutional Activity in HQL
Top Purchases
Top Sells
About HQL
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Insider Transactions at HQL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 04
2025
|
Saba Capital Management, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
6,889
-0.22%
|
$75,779
$11.57 P/Share
|
|
Apr 03
2025
|
Saba Capital Management, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
10,321
-0.33%
|
$123,852
$12.23 P/Share
|
|
Apr 02
2025
|
Saba Capital Management, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
29,102
-0.92%
|
$349,224
$12.28 P/Share
|
|
Apr 01
2025
|
Saba Capital Management, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
17,621
-0.55%
|
$211,452
$12.45 P/Share
|
|
Mar 31
2025
|
Saba Capital Management, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
48,623
-1.5%
|
$583,476
$12.58 P/Share
|
|
Mar 28
2025
|
Saba Capital Management, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
3,602
-0.11%
|
$43,224
$12.95 P/Share
|
|
Mar 27
2025
|
Saba Capital Management, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
32,922
-1.01%
|
$427,986
$13.01 P/Share
|
|
Mar 24
2025
|
Saba Capital Management, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,329
-0.07%
|
$30,277
$13.21 P/Share
|
|
Feb 26
2025
|
Saba Capital Management, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
200
-0.01%
|
$2,600
$13.62 P/Share
|
|
Feb 13
2025
|
Saba Capital Management, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
100
-0.0%
|
$1,300
$13.88 P/Share
|
|
Feb 12
2025
|
Saba Capital Management, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
36,536
-1.1%
|
$474,968
$13.75 P/Share
|
|
Feb 11
2025
|
Saba Capital Management, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
19,756
-0.59%
|
$256,828
$13.77 P/Share
|
|
Feb 10
2025
|
Saba Capital Management, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
42,987
-1.27%
|
$558,831
$13.95 P/Share
|
|
Feb 04
2025
|
Saba Capital Management, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
4,065
-0.12%
|
$56,910
$14.05 P/Share
|
|
Feb 03
2025
|
Saba Capital Management, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,846
-0.05%
|
$25,844
$14.03 P/Share
|
|
Jan 31
2025
|
Saba Capital Management, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
15,143
-0.45%
|
$212,002
$14.27 P/Share
|
|
Jan 30
2025
|
Saba Capital Management, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
21,835
-0.64%
|
$305,690
$14.16 P/Share
|
|
Jan 29
2025
|
Saba Capital Management, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
11,674
-0.34%
|
$163,436
$14.12 P/Share
|
|
Aug 23
2024
|
Bill Maher Director |
BUY
Open market or private purchase
|
Indirect |
650
+27.48%
|
$9,750
$15.37 P/Share
|
|
Jul 16
2024
|
Rose Di Martino Director |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$15,000
$15.53 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 819K shares |
|---|
| Open market or private sale | 306K shares |
|---|